Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 16, 2012.

A. Federal Reserve Bank of Minneapolis (Jacqueline G. King, Community Affairs Officer) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291:

1. *Thomas Watson, Grand Forks, North Dakota, as an individual and as trustee, and Thomas Watson and Toby Kommer,* Fargo, North Dakota, as trustees of the Bank Forward Employee Stock Ownership Plan, Hannaford, North Dakota (''ESOP''), to acquire control of Security State Bank Holding Company, Fargo, North Dakota (''Company''), and thereby indirectly acquire control of Bank Forward, Hannaford, North Dakota. In addition, Mr. Watson and Mr. Kommer, and the ESOP, have applied as a group acting in concert to control Company.

Board of Governors of the Federal Reserve System, June 29, 2012.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 2012–16483 Filed 7–5–12; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Designation of a Class of Employees for Addition to the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HHS gives notice of a decision to designate a class of employees from the Feed Materials Production Center (FMPC) in Fernald, Ohio, also known as the Fernald Environmental Management Project (FEMP), as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On June 27, 2012, the Secretary of HHS designated the following class of employees as an addition to the SEC:

All employees of DOE, DOE contractors, or subcontractors who worked at all locations at the Feed Materials Production Center (FMPC) in Fernald, Ohio, also known as the Fernald Environmental Management Project (FEMP), from January 1, 1968, through December 31, 1978, for a number of work days aggregating at least 250 work days, occurring either solely under this employment or in combination with work days within the parameters established for one or more classes of employees included in the Special Exposure Cohort.

This designation will become effective on July 27, 2012, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the **Federal Register** reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC.

FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 1–877–222–7570. Information requests can also be submitted by email to *DCAS@CDC.GOV.*

John Howard,

Director, National Institute for Occupational Safety and Health.

[FR Doc. 2012–16591 Filed 7–5–12; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Sinae Kim, Ph.D., Emory University: Based on the report of an investigation conducted by Emory University (EU) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Sinae Kim, former Postdoctoral Fellow, Department of Medicine, EU, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL079137, R01 HL084471, and R03 HL096325, and National Institute of General Medical Sciences (NIGMS), NIH, grant RC1 GM092035.

FOR FURTHER INFORMATION CONTACT: John Dahlberg, Ph.D., Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

SUPPLEMENTARY INFORMATION: ORI found that the Respondent engaged in research misconduct by falsifying data that were included in five (5) manuscripts submitted in 2009 for publication to *Blood, Nature, Nature Biotechnology, Nature Medicine,* and *Science,* one (1) poster presented at the 2009 American Heart Association (AHA) meeting, four (4) laboratory meeting presentations, one (1) image file, three (3) funded NIH grants (RC1 GM092035, R01 HL079137, and R03 HL096325), and five (5) submitted NIH grant applications (RC1 HL100648–01, RC2 HL101600–01, RC4 HL106748-01, R01 HD067130–01, and U01 HL107444–01). The manuscripts submitted in 2009 were not accepted for publication.

Specifically, ORI finds that the Respondent knowingly and intentionally:

1. Falsified three (3) figures for immunocytochemistry and alkaline phosphtase (AP) staining images, karyotyping and real-time reverse transcription polymerase chain reaction (RT–PCR) results by using experimental results from her prior work in Korea with human embryonic stem cells (hESCs) to confirm the generation, differentiation, and verification of human induced pluripotent stem cells (iPSCs). The false data were included in:

a. Figures 1c and 2i (panels #4 & 13) in the *Nature* 2009, *Science* 2009, and *Nature Biotechnology* 2009 manuscripts and Supplementary Figure 4 in the *Nature* 2009 manuscript
b. Supplementary Figure 5 in the *Nature Biotechnology* 2009 manuscript
c. Figures S1B and S1D (panels #4 & 13) in the Blood 2009 manuscript
d. Supplementary Figures 8B and 8D (panels #4 & 13) in the *Nature Medicine* 2009 manuscript
e. Figure 9 in the RC1 GM092035 grant
f. Figure 8 in the R01 HL079137 grant
g. Figure 2 in the RC1 HL100648 grant
h. Figure 8 in the RC2 HL101600 grant
i. Figure 3 in the R01 HD067130 grant
j. Figure 1 in the RC4 HL106748 grant
k. Figures 1C, 1H, and 1I (panel #3) in the R03 HL096325 grant
l. Figure 5 in the U01 HL107444 grant
m. Figures 2C and 3I (panels #4 & 13) in the poster presented at the 2009 AHA meeting
n. The presentations 'Figures_Sinae Kim_120808.ppt' and 'Figures_Sinae Kim_121508.ppt'

o. The image file 'HiPS_E1_x100.jpg'

2. Falsified one (1) figure for the real-time RT–PCR data for endogenous SOX2 expression in human iPSCs derived from dermal (HiPS-E1) and cardiac (HiPS-E2) fibroblasts and iPSCs generated from peripheral blood mononuclear cells derived from coronary artery disease patients (HiPS-ECP1, HiPS-ECP2, and HiPS-ECP3) by substituting real-time RT–PCR data for endogenous OCT4 expression in the forementioned cell lines. Specifically, the false data were included in:

a. Figure 2i (panels #2 & 5) in the *Nature* 2009, *Science* 2009, and *Nature Biotechnology* 2009 manuscripts
b. Figure S1D (panels #2 & 5) in the *Blood* 2009 manuscript
c. Supplementary Figure 8D (panels #2 & 5) in the *Nature Medicine* 2009 manuscript
d. Figure 3I (panels #2 & 5) in the poster presented at the 2009 AHA meeting
e. The presentations ''Figures_Sinae Kim_120808.ppt' and 'Figures_Sinae Kim_121508.ppt'

3. Falsified data in two (2) PowerPoint presentations for RT–PCR data of osteogenic-specific gene expression in bone marrow cells by substituting data for RT–PCR data in primary bone-derived and Saos2-osteosarcoma cells.

4. Falsified one (1) figure for the real-time RT–PCR data of OCT4, SOX2, KLF4, c-MYC, NANOG, hTERT, REX1, and GDF3 fold-change expression levels in H1 hESCs, human cardiac and dermal fibroblasts, HiPS-E1, HiPS-E2, HiPS-ECP1, HiPS-ECP2, and HiPS-ECP3 cell lines by substituting data from various other cell lines that did not exist. Specifically, the false data were included in:

a. Figures 2a-h in the *Nature* 2009, *Science* 2009, and *Nature Biotechnology* 2009 manuscripts
b. Figure 10 in the RC1 GM092035 grant
c. Figure 9 in the R01 HL079137 grant
d. Figure 5 in the R01 HD067130 grant
e. Figure 3A–H in the poster presented at the AHA meeting
f. The presentations ''Figures_Sinae Kim_120808.ppt' and 'Figures_Sinae Kim_121508.ppt'

5. Falsified research materials when the Respondent distributed cells to laboratory members that she claimed were chemical/non-viral factor induced-mouse iPSCs and human iPSCs generated from peripheral blood of coronary artery disease patients, when she knew they were of other origin.

Dr. Kim has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of two (2) years, beginning on June 5, 2012:

(1) To exclude herself voluntarily from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ''covered transactions'' pursuant to HHS' Implementation (2 CFR part 376, *et seq*) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ''Debarment Regulations''); and

(2) To exclude herself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

John Dahlberg,

Director, Division of Investigative Oversight, Office of Research Integrity.

[FR Doc. 2012–16572 Filed 7–5–12; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Renewal of Declaration Regarding Emergency Use of All Oral Formulations of Doxycycline Accompanied by Emergency Use Information

AGENCY: Office of the Secretary (OS), HHS.

ACTION: Notice.

SUMMARY: The Secretary of Homeland Security determined on September 23, 2008 that there is a significant potential for a domestic emergency involving a heightened risk of attack with a specified biological, chemical, radiological, or nuclear agent or agents—in this case, Bacillus anthracis. On the basis of that determination, and pursuant to section 564(b) of the Federal Food, Drug, and Cosmetic Act (''FD&C Act''), the Secretary of Health and Human Services is renewing her July 20, 2011 declaration of an emergency justifying the authorization of emergency use of all oral formulations of doxycycline accompanied by emergency use information subject to the terms of any authorization issued by the Commissioner of Food and Drugs under 21 U.S.C. 360bbb–3(a). This notice is being issued in accordance with section 564(b)(4) of the FD&C Act, 21 U.S.C. 360bbb–3(b)(4).

DATES: This Notice and referenced HHS declaration are effective as of July 20, 2012.

FOR FURTHER INFORMATION CONTACT: Nicole Lurie, MD, MSPH, Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, 200 Independence Avenue SW., Washington, DC 20201, Telephone (202) 205–2882 (this is not a toll free number).

SUPPLEMENTARY INFORMATION: On September 23, 2008, former Secretary of Homeland Security, Michael Chertoff, determined that there is a significant potential for a domestic emergency, involving a heightened risk of attack with a specified biological, chemical, radiological, or nuclear agent or agents—in this case, *Bacillus anthracis*—although there is no current domestic emergency involving anthrax, no current heightened risk of an anthrax attack, and no credible information indicating an imminent threat of an attack involving *Bacillus anthracis.*

On October 1, 2008, on the basis of that determination, and pursuant to section 564(b) of the FD&C Act, 21 U.S.C. 360bbb–3(b), former Secretary of Health and Human Services, Michael O. Leavitt, declared an emergency justifying the emergency use of doxycycline hyclate tablets accompanied by emergency use information subject to the terms of any authorization issued under 21 U.S.C. 360bbb–3(a).[1] On October 1, 2009 and October 1, 2010, I renewed the former Secretary's declaration,[2] and on July 20, 2011, I renewed and amended the declaration to declare that the emergency justifies emergency use of all oral formulations of doxycycline accompanied by emergency use information subject to the terms of any authorization issued under 21 U.S.C. 360bbb–3(a).[3]

On the basis of the September 23, 2008 determination by the Secretary of Homeland Security and pursuant to section 564(b) of the FD&C Act, I hereby renew my July 20, 2011 declaration that the emergency justifies emergency use of all oral formulations of doxycycline accompanied by emergency use information subject to the terms of any authorization issued under 21 U.S.C. § 360bbb–3(a). I am issuing this notice in accordance with section 564(b)(4) of

[1] Pursuant to section 564(b)(4) of the FD&C Act, notice of the determination by the Secretary of Homeland Security and the declaration by the Secretary of Health and Human Services was provided at 73 FR 58242 (October 6, 2008).

[2] Pursuant to section 564(b)(4) of the FD&C Act, notices of the renewal of the declaration of the Secretary of Health and Human Services were provided at 74 FR 51,279 (Oct. 6, 2009) and 75 FR 61,489 (Oct. 5, 2010).

[3] Pursuant to section 564(b)(4) of the FD&C Act, notice of the renewal and amendment of the declaration of the Secretary of Health and Human Services was provided at 76 FR 44,926 (July 27, 2011).